Vertex Pharmaceuticals - VRTX Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $429.45
Forecasted Upside: 8.92%
Number of Analysts: 23
Breakdown:
3 Sell Ratings
6 Hold Ratings
14 Buy Ratings
0 Strong Buy Ratings

^$394.28 As of 04/19/2024 01:00 AM ET

▲ +0.8 (0.20%)

1 month | 3 months | 12 months

Get New Vertex Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for VRTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VRTX

^$429.45

▲ +8.92% Upside Potential

This price target is based on 23 analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is $429.45, with a high forecast of $540.00 and a low forecast of $325.00. The average price target represents a 8.92% upside from the last price of $394.28.

Current Consensus is Hold

The current consensus among 23 polled investment analysts is to hold stock in Vertex Pharmaceuticals. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
14 buy ratings
6 hold ratings
3 sell ratings

Ratings as of

10/27/2022

0 strong buy ratings
14 buy ratings
6 hold ratings
3 sell ratings

Ratings as of

1/25/2023

0 strong buy ratings
14 buy ratings
6 hold ratings
3 sell ratings

Ratings as of

4/25/2023

0 strong buy ratings
14 buy ratings
6 hold ratings
3 sell ratings

Ratings as of

7/24/2023

0 strong buy ratings
14 buy ratings
6 hold ratings
3 sell ratings

Ratings as of

10/22/2023

0 strong buy ratings
14 buy ratings
6 hold ratings
3 sell ratings

Ratings as of

1/20/2024

0 strong buy ratings
14 buy ratings
6 hold ratings
3 sell ratings

Ratings as of

3/20/2024

0 strong buy ratings
14 buy ratings
6 hold ratings
3 sell ratings

Ratings as of

4/19/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/18/2024	Guggenheim	Boost Target	Buy ➝ Buy	$445.00 ➝ $450.00	Low
4/17/2024	UBS Group	Lower Target	Buy ➝ Buy	$498.00 ➝ $466.00	Low
4/15/2024	Oppenheimer	Reiterated Rating	Outperform ➝ Outperform	$500.00	Low
4/12/2024	Canaccord Genuity Group	Reiterated Rating	Sell ➝ Sell	$371.00	Low
4/11/2024	Evercore ISI	Upgrade	In-Line ➝ Outperform	$438.00	Low
4/11/2024	HC Wainwright	Boost Target	Buy ➝ Buy	$457.00 ➝ $462.00	Low
2/20/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$440.00	Low
2/15/2024	Wolfe Research	Initiated Coverage	Outperform	$515.00	Low
2/6/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$440.00	Low
2/6/2024	Royal Bank of Canada	Boost Target	Sector Perform ➝ Sector Perform	$397.00 ➝ $420.00	Low
2/6/2024	Wells Fargo & Company	Boost Target	Overweight ➝ Overweight	$500.00 ➝ $540.00	Low
2/6/2024	Barclays	Boost Target	Overweight ➝ Overweight	$446.00 ➝ $472.00	Low
2/6/2024	William Blair	Reiterated Rating	Outperform		Low
2/6/2024	Evercore ISI	Downgrade	Outperform ➝ In-Line	$436.00 ➝ $438.00	Low
2/6/2024	HC Wainwright	Boost Target	Buy ➝ Buy	$397.00 ➝ $457.00	Low
2/2/2024	Sanford C. Bernstein	Downgrade	Outperform ➝ Market Perform		Low
2/1/2024	JPMorgan Chase & Co.	Boost Target	Overweight ➝ Overweight	$390.00 ➝ $438.00	Low
1/31/2024	Truist Financial	Boost Target	Buy ➝ Buy	$456.00 ➝ $508.00	Low
1/31/2024	Robert W. Baird	Downgrade	Neutral ➝ Underperform	$325.00	Low
1/31/2024	Maxim Group	Downgrade	Buy ➝ Hold		Low
1/24/2024	Cantor Fitzgerald	Boost Target	Overweight ➝ Overweight	$415.00 ➝ $440.00	Low
1/24/2024	Canaccord Genuity Group	Reiterated Rating	Hold ➝ Sell	$332.00 ➝ $379.00	Low
1/24/2024	Canaccord Genuity Group	Downgrade	Hold ➝ Sell	$332.00 ➝ $379.00	Low
1/9/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$415.00	Low
12/14/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$380.00	Low
12/14/2023	Royal Bank of Canada	Boost Target	Sector Perform ➝ Sector Perform	$347.00 ➝ $379.00	Low
12/11/2023	Barclays	Boost Target	Overweight ➝ Overweight	$408.00 ➝ $415.00	Low
12/11/2023	HC Wainwright	Boost Target	Buy ➝ Buy	$390.00 ➝ $397.00	Low
12/5/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$380.00	Low
11/22/2023	Stifel Nicolaus	Reiterated Rating	Hold ➝ Hold	$373.00	Low
11/16/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$380.00	Low
11/8/2023	Morgan Stanley	Boost Target	Equal Weight ➝ Equal Weight	$359.00 ➝ $364.00	Low
11/7/2023	Royal Bank of Canada	Lower Target	Sector Perform ➝ Sector Perform	$350.00 ➝ $347.00	Low
11/7/2023	BMO Capital Markets	Boost Target	Outperform ➝ Outperform	$389.00 ➝ $415.00	Low
11/7/2023	Cantor Fitzgerald	Boost Target	Overweight ➝ Overweight	$370.00 ➝ $380.00	Low
11/7/2023	Stifel Nicolaus	Boost Target	Hold ➝ Hold	$340.00 ➝ $373.00	Low
11/7/2023	HC Wainwright	Boost Target	Buy ➝ Buy	$380.00 ➝ $390.00	Low
10/16/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$370.00	Low
10/9/2023	Morgan Stanley	Boost Target	Equal Weight ➝ Equal Weight	$352.00 ➝ $359.00	Low
10/4/2023	Truist Financial	Reiterated Rating	Buy ➝ Buy	$456.00	Low
9/29/2023	Royal Bank of Canada	Boost Target	Sector Perform ➝ Sector Perform	$343.00 ➝ $348.00	Low
9/7/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$370.00	Low
8/7/2023	Canaccord Genuity Group	Boost Target	Hold ➝ Hold	$312.00 ➝ $315.00	Low
8/2/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$380.00	Low
8/2/2023	Oppenheimer	Reiterated Rating	Outperform ➝ Outperform	$410.00	Low
8/2/2023	BMO Capital Markets	Boost Target	Outperform ➝ Outperform	$385.00 ➝ $389.00	Low
8/2/2023	Morgan Stanley	Boost Target	Equal Weight ➝ Equal Weight	$340.00 ➝ $352.00	N/A
8/2/2023	Royal Bank of Canada	Boost Target	Sector Perform ➝ Sector Perform	$325.00 ➝ $343.00	N/A
8/2/2023	Wells Fargo & Company	Boost Target	Overweight ➝ Overweight	$410.00 ➝ $425.00	Low
8/2/2023	Sanford C. Bernstein	Boost Target	Outperform ➝ Outperform	$380.00 ➝ $390.00	Low
8/2/2023	Barclays	Boost Target	Overweight ➝ Overweight	$384.00 ➝ $399.00	Low
7/21/2023	Bank of America	Boost Target	Buy	$350.00 ➝ $400.00	Low
7/3/2023	Morgan Stanley	Boost Target	Equal Weight ➝ Equal Weight	$305.00 ➝ $340.00	Low
6/26/2023	888	Reiterated Rating	Reiterates		Low
6/26/2023	Evercore ISI	Boost Target		$375.00 ➝ $379.00	Low
6/8/2023	Royal Bank of Canada	Boost Target		$315.00 ➝ $323.00	Low
5/30/2023	William Blair	Initiated Coverage	Outperform	$382.00	Low
5/25/2023	Westpark Capital	Initiated Coverage	Hold		Low
5/3/2023	Maxim Group	Boost Target		$325.00 ➝ $400.00	Low
5/3/2023	Sanford C. Bernstein	Boost Target		$344.00 ➝ $363.00	Low
5/2/2023	Royal Bank of Canada	Boost Target		$299.00 ➝ $315.00	Low
5/2/2023	Truist Financial	Boost Target		$341.00 ➝ $456.00	Low
5/2/2023	Stifel Nicolaus	Boost Target		$300.00 ➝ $340.00	Low
5/2/2023	Guggenheim	Boost Target		$339.00 ➝ $385.00	Low
5/2/2023	Robert W. Baird	Boost Target		$280.00 ➝ $325.00	Low
5/2/2023	Oppenheimer	Boost Target		$350.00 ➝ $410.00	Low
5/2/2023	HC Wainwright	Boost Target		$326.00 ➝ $380.00	Low
5/2/2023	Barclays	Boost Target		$342.00 ➝ $384.00	Low
3/29/2023	Argus	Boost Target	Buy	$340.00 ➝ $350.00	Low
3/21/2023	Sanford C. Bernstein	Initiated Coverage	Outperform	$344.00	Low
2/8/2023	Morgan Stanley	Lower Target	Equal Weight	$286.00 ➝ $285.00	Low
2/8/2023	Piper Sandler	Reiterated Rating	Neutral	$296.00	Low
2/8/2023	SVB Securities	Lower Target		$374.00 ➝ $365.00	Low
2/8/2023	SVB Leerink	Lower Target	Outperform	$374.00 ➝ $365.00	Low
2/8/2023	HC Wainwright	Boost Target	Buy	$300.00 ➝ $325.00	Low
2/8/2023	Barclays	Boost Target	Overweight	$313.00 ➝ $342.00	Low
1/24/2023	Morgan Stanley	Boost Target	Equal Weight	$285.00 ➝ $286.00	Low
1/19/2023	Piper Sandler	Boost Target	Neutral	$293.00 ➝ $296.00	Low
1/18/2023	Canaccord Genuity Group	Initiated Coverage	Hold	$311.00	Low
1/17/2023	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$374.00	Low
12/19/2022	Jefferies Financial Group	Downgrade	Buy ➝ Hold	$340.00	Low
11/17/2022	Argus	Boost Target	Buy	$320.00 ➝ $340.00	Low
11/1/2022	Guggenheim	Boost Target		$318.00	Low
11/1/2022	Robert W. Baird	Boost Target		$280.00	Low
10/28/2022	Royal Bank of Canada	Boost Target	Sector Perform	$281.00 ➝ $288.00	Low
10/28/2022	Barclays	Boost Target	Overweight	$307.00 ➝ $313.00	Low
10/28/2022	Morgan Stanley	Boost Target	Equal Weight	$253.00 ➝ $285.00	Low
10/28/2022	Wells Fargo & Company	Boost Target	Overweight	$305.00 ➝ $335.00	Low
10/28/2022	Cowen	Boost Target		$315.00 ➝ $330.00	Low
10/28/2022	Cowen	Boost Target		$315.00 ➝ $330.00	Low
10/24/2022	JPMorgan Chase & Co.	Boost Target	Overweight	$319.00 ➝ $327.00	Low
10/16/2022	Piper Sandler	Boost Target		$288.00 ➝ $293.00	Low
8/16/2022	Piper Sandler	Boost Target	Neutral	$256.00 ➝ $288.00	Low
8/8/2022	Morgan Stanley	Boost Target	Equal Weight	$250.00 ➝ $253.00	Low
8/5/2022	HC Wainwright	Boost Target	Buy	$275.00 ➝ $300.00	Low
8/5/2022	Barclays	Boost Target	Overweight	$291.00 ➝ $307.00	Low
7/26/2022	Piper Sandler	Boost Target	Neutral	$242.00 ➝ $256.00	Low
7/12/2022	Cantor Fitzgerald	Initiated Coverage	Overweight	$365.00	N/A
6/13/2022	Cowen	Boost Target	Outperform	$305.00 ➝ $310.00	Medium
6/13/2022	Argus	Boost Target	Buy	$275.00 ➝ $280.00	High
6/13/2022	Cowen	Boost Target		$305.00 ➝ $310.00	High
6/1/2022	Maxim Group	Upgrade	Hold ➝ Buy	$325.00	Medium
5/23/2022	SVB Leerink	Initiated Coverage	Market Perform	$265.00	High
5/6/2022	Wells Fargo & Company	Boost Target		$300.00 ➝ $305.00	Medium
5/6/2022	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$250.00	Medium
5/6/2022	Piper Sandler	Lower Target		$249.00 ➝ $242.00	Medium
5/3/2022	Morgan Stanley	Upgrade	Underweight ➝ Equal Weight	$250.00	Medium
4/21/2022	Piper Sandler	Boost Target	Neutral	$245.00 ➝ $249.00	High
4/13/2022	UBS Group	Boost Target		$258.00 ➝ $325.00	High
4/5/2022	Wells Fargo & Company	Boost Target	Overweight	$270.00 ➝ $300.00	N/A
4/4/2022	Oppenheimer	Boost Target		$305.00 ➝ $350.00	Low
3/23/2022	HC Wainwright	Reiterated Rating	Buy	$275.00	High
2/3/2022	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform	$269.00	Medium
1/27/2022	Wolfe Research	Boost Target	Outperform	$271.00 ➝ $282.00	Low
1/27/2022	JPMorgan Chase & Co.	Boost Target	Overweight	$260.00 ➝ $288.00	Low
1/27/2022	Royal Bank of Canada	Boost Target	Outperform ➝ Outperform	$268.00 ➝ $269.00	Low
1/27/2022	Stifel Nicolaus	Boost Target	Hold	$213.00 ➝ $222.00	Low
1/27/2022	Morgan Stanley	Boost Target	Underweight	$203.00 ➝ $208.00	Low
1/20/2022	BMO Capital Markets	Upgrade	Market Perform ➝ Outperform	$202.00 ➝ $274.00	Medium
12/23/2021	Evercore ISI	Reiterated Rating	Buy	$265.00	Low
12/8/2021	Wells Fargo & Company	Initiated Coverage	Overweight	$270.00	Low
12/2/2021	Royal Bank of Canada	Boost Target	Fair Value ➝ Outperform	$250.00 ➝ $265.00	Low
11/18/2021	BMO Capital Markets	Initiated Coverage	Market Perform	$202.00	Medium
11/18/2021	Piper Sandler	Downgrade	Overweight ➝ Neutral	$323.00 ➝ $218.00	Low
11/3/2021	Royal Bank of Canada	Boost Target	Outperform	$246.00 ➝ $250.00	High
9/9/2021	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$244.00 ➝ $213.00	Medium
9/7/2021	Morgan Stanley	Downgrade	Equal Weight ➝ Underweight	$202.00	High
7/30/2021	Morgan Stanley	Lower Target	Equal Weight	$205.00 ➝ $202.00	Low
7/30/2021	Royal Bank of Canada	Boost Target	Outperform	$246.00 ➝ $248.00	Low
7/30/2021	SVB Leerink	Boost Target	Underperform	$170.00 ➝ $175.00	Low
7/30/2021	Piper Sandler	Boost Target	Overweight	$261.00 ➝ $323.00	Low
7/20/2021	SVB Leerink	Downgrade	Market Perform ➝ Underperform	$200.00 ➝ $170.00	Low
7/19/2021	Wolfe Research	Initiated Coverage	Outperform	$252.00	Low
6/30/2021	Raymond James	Initiated Coverage	Market Perform		Low
6/14/2021	Truist Financial	Boost Target	Buy	$305.00 ➝ $331.00	Low
6/14/2021	Piper Sandler	Lower Target	Overweight	$347.00 ➝ $261.00	Low
6/14/2021	SVB Leerink	Lower Target	Reduce ➝ Market Perform	$250.00 ➝ $200.00	Low
6/13/2021	Evercore ISI	Reiterated Rating	Buy		Low
6/11/2021	Stifel Nicolaus	Lower Target	Buy	$277.00 ➝ $244.00	High
6/11/2021	The Goldman Sachs Group	Lower Target	Buy	$358.00 ➝ $307.00	High
6/11/2021	Barclays	Lower Target	Overweight	$302.00 ➝ $285.00	High
6/11/2021	Cantor Fitzgerald	Lower Target	Overweight	$285.00 ➝ $281.00	High
6/11/2021	Morgan Stanley	Lower Target	Equal Weight	$254.00 ➝ $205.00	High
6/11/2021	Robert W. Baird	Lower Target	Outperform	$252.00 ➝ $240.00	High
6/11/2021	Royal Bank of Canada	Lower Target	Positive ➝ Outperform	$262.00 ➝ $242.00	High
6/11/2021	Daiwa Capital Markets	Downgrade	Outperform ➝ Neutral	$210.00	High
5/3/2021	Morgan Stanley	Boost Target	Equal Weight	$253.00 ➝ $254.00	Low
4/26/2021	Morgan Stanley	Boost Target	Equal Weight	$253.00 ➝ $254.00	N/A
4/19/2021	Morgan Stanley	Boost Target	Equal Weight	$251.00 ➝ $253.00	Low
4/11/2021	Royal Bank of Canada	Reiterated Rating	Buy		Low
2/23/2021	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$220.00 ➝ $252.00	Medium
2/2/2021	BMO Capital Markets	Lower Target	Outperform	$302.00 ➝ $284.00	Low
2/2/2021	Credit Suisse Group	Lower Target	Outperform	$285.00 ➝ $280.00	Low
2/2/2021	SVB Leerink	Lower Target	Market Perform	$257.00 ➝ $250.00	Low
2/2/2021	Piper Sandler	Boost Target	Overweight	$307.00 ➝ $347.00	Low
2/2/2021	HC Wainwright	Lower Target	Buy	$315.00 ➝ $275.00	Low
1/19/2021	Morgan Stanley	Boost Target	Equal Weight	$249.00 ➝ $251.00	Low
12/30/2020	Daiwa Capital Markets	Initiated Coverage	Outperform	$250.00	N/A
12/11/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low
11/30/2020	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$247.00 ➝ $267.00	Low
11/20/2020	Sanford C. Bernstein	Initiated Coverage	Outperform	$275.00	Low
11/1/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low
10/30/2020	Piper Sandler	Lower Target	Overweight	$327.00 ➝ $307.00	Low
10/30/2020	Credit Suisse Group	Lower Target	Outperform	$292.00 ➝ $285.00	Low
10/30/2020	SVB Leerink	Lower Target	Market Perform	$267.00 ➝ $257.00	High
10/28/2020	UBS Group	Initiated Coverage	Buy	$287.00	Low
10/26/2020	Needham & Company LLC	Reiterated Rating	Hold		Medium
10/19/2020	Morgan Stanley	Lower Target	Equal Weight	$281.00 ➝ $249.00	Medium
10/15/2020	Truist Financial	Lower Target		$330.00 ➝ $305.00	High
10/15/2020	SVB Leerink	Lower Target	Market Perform	$283.00 ➝ $267.00	High
10/13/2020	Morgan Stanley	Lower Target	Equal Weight	$300.00 ➝ $281.00	Low
9/18/2020	Maxim Group	Reiterated Rating	Hold		High
8/24/2020	SVB Leerink	Boost Target	Neutral ➝ Market Perform	$274.00 ➝ $283.00	Medium
7/31/2020	Cantor Fitzgerald	Boost Target	Overweight	$293.00 ➝ $305.00	High
7/31/2020	SVB Leerink	Boost Target	Market Perform	$263.00 ➝ $274.00	High
7/31/2020	HC Wainwright	Reiterated Rating	Buy	$295.00 ➝ $315.00	High
7/31/2020	Piper Sandler	Boost Target	Overweight	$302.00 ➝ $327.00	High
7/20/2020	Credit Suisse Group	Boost Target	Outperform	$298.00 ➝ $328.00	High
7/16/2020	Cowen	Boost Target	Outperform	$265.00 ➝ $300.00	Low
7/14/2020	Jefferies Financial Group	Boost Target	Buy	$295.00 ➝ $340.00	High
7/8/2020	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$277.00 ➝ $300.00	Medium
7/2/2020	The Goldman Sachs Group	Boost Target	Positive ➝ Conviction-Buy	$290.00 ➝ $330.00	Low
6/24/2020	SunTrust Banks	Boost Target	Buy	$285.00 ➝ $330.00	High
6/12/2020	Citigroup	Boost Target	Top Pick ➝ Buy	$305.00 ➝ $325.00	Low
5/15/2020	Argus	Boost Target	Buy	$270.00 ➝ $320.00	High
5/1/2020	Citigroup	Boost Target	Buy	$265.00 ➝ $305.00	Medium
4/30/2020	Credit Suisse Group	Reiterated Rating	Buy	$298.00	Medium
4/30/2020	Cfra	Boost Target	Buy	$286.00 ➝ $297.00	Low
4/30/2020	Guggenheim	Boost Target	Buy	$266.00 ➝ $290.00	High
4/30/2020	BMO Capital Markets	Boost Target	Outperform	$279.00 ➝ $283.00	High
4/30/2020	Stifel Nicolaus	Boost Target	Buy	$275.00 ➝ $285.00	High
4/30/2020	Oppenheimer	Boost Target	Outperform	$265.00 ➝ $305.00	High
4/30/2020	Morgan Stanley	Boost Target	Overweight	$258.00 ➝ $277.00	High
4/30/2020	SVB Leerink	Boost Target	Market Perform	$224.00 ➝ $263.00	High
4/30/2020	JMP Securities	Boost Target	Market Outperform	$255.00 ➝ $285.00	High
4/30/2020	HC Wainwright	Boost Target	Buy	$270.00 ➝ $295.00	High
4/28/2020	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform	$250.00 ➝ $260.00	High
4/27/2020	Piper Sandler	Reiterated Rating	Buy	$300.00	High
4/15/2020	Morgan Stanley	Boost Target	Overweight	$251.00 ➝ $258.00	Medium
3/27/2020	Piper Sandler	Reiterated Rating	Buy	$300.00	High
3/12/2020	Wolfe Research	Initiated Coverage	Outperform	$282.00	High
3/11/2020	Cantor Fitzgerald	Reiterated Rating	Overweight	$262.00 ➝ $275.00	Medium
3/4/2020	Barclays	Initiated Coverage	Overweight	$271.00	High
3/3/2020	Cowen	Reiterated Rating	Buy	$260.00	Medium
3/2/2020	Argus	Boost Target	Positive ➝ Buy	$248.00 ➝ $270.00	High
2/2/2020	Evercore ISI	Reiterated Rating	Hold	$270.00	Medium
1/31/2020	Piper Sandler	Boost Target		$284.00 ➝ $300.00	Medium
1/31/2020	Bank of America	Reiterated Rating	Buy	$250.00 ➝ $295.00	High
1/31/2020	Needham & Company LLC	Reiterated Rating	Hold		High
1/31/2020	Morgan Stanley	Boost Target	Overweight	$250.00 ➝ $251.00	Low
1/31/2020	Stifel Nicolaus	Boost Target	Buy	$243.00 ➝ $275.00	High
1/31/2020	Royal Bank of Canada	Boost Target	Outperform	$240.00 ➝ $260.00	High
1/31/2020	Cfra	Boost Target	Buy	$237.00 ➝ $286.00	High
1/31/2020	Credit Suisse Group	Boost Target	Outperform	$253.00 ➝ $258.00	High
1/31/2020	SunTrust Banks	Reiterated Rating	Buy	$285.00	High
1/31/2020	JPMorgan Chase & Co.	Boost Target	Overweight	$247.00 ➝ $260.00	High
1/31/2020	HC Wainwright	Boost Target	Buy	$220.00 ➝ $270.00	High
1/31/2020	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$210.00 ➝ $230.00	High
1/14/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low
1/9/2020	BMO Capital Markets	Boost Target		$248.00 ➝ $268.00	Low
1/8/2020	Oppenheimer	Boost Target	Outperform	$230.00 ➝ $265.00	Low
1/6/2020	Piper Sandler Companies	Boost Target	Overweight	$247.00 ➝ $284.00	N/A
1/2/2020	Raymond James	Downgrade	Outperform ➝ Market Perform		Low
12/18/2019	JPMorgan Chase & Co.	Boost Target	Overweight	$218.00 ➝ $247.00	Low
12/16/2019	Argus	Boost Target	Buy	$248.00	Medium
12/13/2019	Credit Suisse Group	Upgrade	Buy	$231.00	Low
11/20/2019	BMO Capital Markets	Boost Target	Outperform ➝ Positive	$248.00	Low
11/19/2019	Cowen	Reiterated Rating	Buy		Low
11/19/2019	Guggenheim	Upgrade	Neutral ➝ Buy	$252.00	High
11/12/2019	SunTrust Banks	Initiated Coverage	Buy	$235.00	Medium
11/4/2019	Credit Suisse Group	Reiterated Rating	Buy	$228.00	Low
11/1/2019	Maxim Group	Reiterated Rating	Hold		High
10/31/2019	Piper Sandler Companies	Boost Target	Overweight	$230.00 ➝ $247.00	High
10/22/2019	Credit Suisse Group	Boost Target	Overweight	$213.00 ➝ $221.00	Low
10/22/2019	SVB Leerink	Boost Target	Market Perform	$186.00 ➝ $203.00	High
10/22/2019	Citigroup	Boost Target	Buy	$205.00 ➝ $225.00	High
10/21/2019	BMO Capital Markets	Set Target	Buy	$232.00	Medium
10/21/2019	Jefferies Financial Group	Set Target	Buy	$220.00	Medium
10/21/2019	Cowen	Set Target	Buy	$220.00	Medium
10/21/2019	Robert W. Baird	Set Target	Buy	$210.00	Medium
10/21/2019	JPMorgan Chase & Co.	Set Target	Buy	$218.00	Medium
10/16/2019	Bank of America	Initiated Coverage	Buy	$220.00	Medium
9/23/2019	Jefferies Financial Group	Boost Target		$210.00 ➝ $220.00	Medium
9/6/2019	Morgan Stanley	Boost Target	Overweight	$215.00 ➝ $240.00	Low
9/3/2019	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$226.00 ➝ $254.00	High
8/12/2019	Royal Bank of Canada	Set Target	Buy	$213.00	Low
8/2/2019	Maxim Group	Reiterated Rating	Hold		Low
8/1/2019	Credit Suisse Group	Boost Target	Outperform	$209.00 ➝ $213.00	Low
8/1/2019	Piper Sandler Companies	Boost Target	Overweight	$217.00 ➝ $230.00	Low
8/1/2019	Stifel Nicolaus	Boost Target	Buy	$205.00 ➝ $211.00	Low
8/1/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy	$212.00	High
8/1/2019	HC Wainwright	Reiterated Rating	Buy	$220.00	High
8/1/2019	Needham & Company LLC	Downgrade	Buy ➝ Hold		High
7/31/2019	Cowen	Set Target	Buy	$220.00	N/A
6/2/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low
5/23/2019	The Goldman Sachs Group	Reiterated Rating	Buy	$220.00	Low
5/23/2019	Citigroup	Reiterated Rating	Buy ➝ Buy	$205.00	Low
5/20/2019	Credit Suisse Group	Initiated Coverage	Outperform	$209.00 ➝ $209.00	Medium
5/1/2019	Needham & Company LLC	Reiterated Rating	Buy	$195.00	Low
5/1/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy	$209.00	High
4/30/2019	Cowen	Reiterated Rating	Buy	$220.00	High

(Data available from 4/19/2019 forward)

News Sentiment Rating

0.82 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

22 very positive mentions
11 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

9/22/2023

23 very positive mentions
11 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

10/22/2023

8 very positive mentions
21 positive mentions
0 negative mentions
8 very negative mentions

Mentions as of

11/21/2023

35 very positive mentions
27 positive mentions
4 negative mentions
5 very negative mentions

Mentions as of

12/21/2023

31 very positive mentions
25 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

1/20/2024

61 very positive mentions
39 positive mentions
7 negative mentions
2 very negative mentions

Mentions as of

2/19/2024

48 very positive mentions
23 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

3/20/2024

53 very positive mentions
36 positive mentions
4 negative mentions
1 very negative mentions

Mentions as of

4/19/2024

Current Sentiment

Recent Stories by Sentiment

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $394.28

$391.25

$396.98

50 Day Range

MA: $414.17

$393.10

$433.48

52 Week Range

Now: $394.28

$316.43

$448.40

Volume

1,342,016 shs

Average Volume

1,246,165 shs

Market Capitalization

$101.91 billion

P/E Ratio

28.39

Dividend Yield

N/A

Beta

0.35

Frequently Asked Questions

What sell-side analysts currently cover shares of Vertex Pharmaceuticals?: The following Wall Street analysts have issued stock ratings on Vertex Pharmaceuticals in the last twelve months: 888 Holdings plc, Bank of America Co., Barclays PLC, BMO Capital Markets, Canaccord Genuity Group Inc., Cantor Fitzgerald, Evercore ISI, Guggenheim, HC Wainwright, JPMorgan Chase & Co., Maxim Group, Morgan Stanley, Oppenheimer Holdings Inc., Robert W. Baird, Royal Bank of Canada, Sanford C. Bernstein, Stifel Nicolaus, StockNews.com, Truist Financial Co., UBS Group AG, Wells Fargo & Company, Westpark Capital, William Blair, and Wolfe Research.
View the latest analyst ratings for VRTX.
What is the current price target for Vertex Pharmaceuticals?: 22 Wall Street analysts have set twelve-month price targets for Vertex Pharmaceuticals in the last year. Their average twelve-month price target is $429.45, suggesting a possible upside of 8.9%. Wells Fargo & Company has the highest price target set, predicting VRTX will reach $540.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $325.00 for Vertex Pharmaceuticals in the next year.
View the latest price targets for VRTX.
What is the current consensus analyst rating for Vertex Pharmaceuticals?: Vertex Pharmaceuticals currently has 3 sell ratings, 6 hold ratings and 14 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in VRTX, but not buy more shares or sell existing shares.
View the latest ratings for VRTX.
What other companies compete with Vertex Pharmaceuticals?: Other companies that are similar to Vertex Pharmaceuticals include Regeneron Pharmaceuticals, Bristol-Myers Squibb, Sanofi, GSK and Zoetis. Learn More about companies similar to Vertex Pharmaceuticals.
How do I contact Vertex Pharmaceuticals' investor relations team?: Vertex Pharmaceuticals' physical mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company's listed phone number is (617) 341-6100 and its investor relations email address is [email protected]. The official website for Vertex Pharmaceuticals is www.vrtx.com. Learn More about contacing Vertex Pharmaceuticals investor relations.

Vertex Pharmaceuticals - VRTX Stock Price Target and Predictions

Analyst Price Target for VRTX

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.82 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Vertex Pharmaceuticals?

What is the current price target for Vertex Pharmaceuticals?

What is the current consensus analyst rating for Vertex Pharmaceuticals?

What other companies compete with Vertex Pharmaceuticals?

How do I contact Vertex Pharmaceuticals' investor relations team?